BNF:

4.3.1

Status:

Grey

Decision Date:

December 2016

Comments

GREY: for use in neuropathic pain as alternative to amitriptyline if treatment effective but not tolerated (Decision date - April 2023)

GREY: a treatment option as an adjunct in treatment resistant depression. (Decision date - Jan 2017)

Grey Drug Classifications

• 5: Less cost-effective than current standard therapy

search again